Is a controlled randomised trial the non-plus-ultra design? A contribution to discussion on comparative, controlled, non-randomised trials

Contemporary Clinical Trials

Volumn 35, Issue 1, 2013, Pages 127-132

  Gaus, Wilhelm ^a   Muche, Rainer ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Clinical Trials; Discussion; Methodology; Non randomised Trials; Randomisation

Indexed keywords

INTERFERON;

ALTERNATIVE MEDICINE; BREAST CANCER; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPARATIVE STUDY; DIET THERAPY; DOCTOR PATIENT RELATION; EFFECT SIZE; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; GOOD CLINICAL PRACTICE; GUINEA PIG; HEALING; HEPATITIS C; HUMAN; INFORMED CONSENT; INTERNAL VALIDITY; LIFE SATISFACTION; LIVER CIRRHOSIS; METHODOLOGY; NONHUMAN; NOTE; OBESITY; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICIAN; PHYSIOTHERAPY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TENSION HEADACHE; TREATMENT INDICATION; WALKING;

BIOMEDICAL RESEARCH; HUMANS; INFORMED CONSENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876338904     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.02.011     Document Type: Note

References (30)

1. Högel J., Gaus W. The procedure of new drug application and the philosophy of "critical rationalism" or the limits of quality assurance with "good clinical practice". Control Clin Trials 1999, 20:511-518.
2. Porzolt F., Kliemt H. Ethische und empirische Grenzen randomisierter kontrollierter Studien. Med Klin 2008, 103:836-842.
3. Kleijnen J., de Craen J.M., van Everdingen J., et al. Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet 1994, 344:1347-1349.
4. Kaptchuk T.J. Powerful placebo: the dark side of the randomised controlled trial. Lancet 1998, 351:1722-1725.
5. Kaptchuk T.J. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?. J Clin Epidemiol 2001, 54:541-549.
6. Kaptchuk T.J., Kelly J.M., Conoy L.A., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008, [online first]. 10.1136/bmj.39524.439618.25.
7. MacLehose R.R., Reeves B.C., Harvey I.M., et al. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess 2000, 4(34):1-154.
8. Kaptchuk T.J., Shaw J., Kerr C.E. "Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trial. Cult Med Psychiatry 2009, 33:382-411. 10.1007/s11013-009-9141-7.
9. Skovlund E. Should we tell patients that they might receive placebo?. Lancet 1991, 337:1041.
10. Colagiuri B., Boakes R.A. Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis. Psychopharmacology 2010, 208:433-441. 10.1007/s00213-009-1743-9.
11. Gehr B.T., Weiss Ch., Porzsolt F. The fading of reported effectiveness. A meta-analysis of randomised controlled trials. BMC Med Res Methodol 2006, 6:25. 10.1186/1471-2288-6-25.
12. Ethgen M., Boutron I., Steg P.G., et al. Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention. BMC Med Res Methodol 2009, 9:24. 10.1186/1471-2288-9-24.
13. Gaus W., Chase D. Klinische Studien: Regelwerke, Strukturen, Dokumente, Daten 2007, Books on Demand, Norderstedt. 2nd ed.
14. Bergmann J.F., Chassany O., Gandiol J., et al. A randomised clinical trial of the effect of randomised consent on the analgesic efficacy of placebo and naproxen in cancer pain. Clin Trials Metaanal 1994, 29:41-47.
15. Horwitz R.I., Horwitz S.M. Adherence to treatment and health outcomes. Arch Intern Med 1993, 153:1863-1868.
16. Bajard A., Chabaud S., Perol D., et al. Revisiting the level of evidence in randomized controlled trials: a simulation approach. Contemp Clin Trials 2009, 30:400-410.
17. Comparative observational studies in clinical research. Research in complementary and classical natural medicine 2004, 11, Suppl. 1:1-55. S. Karger Verlag, Basel. R. Ziegler, W. Gaus (Eds.).
18. McCarron C.E., Pullenayegum E.M., Thabane L., et al. The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms. BMC Med Res Methodol 2010, 10:64. 10.1186/1471-2288-10-64.
19. Schmoor C., Caputo A., Schumacher M. Evidence from nonrandomized studies: a case study on the estimation of causal effects. Am J Epidemiol 2008, 167:1120-1129. 10.1093/aje/kwn010.
20. Schmoor C., Gall C., Stampf S., et al. Correction of confounding bias in non-randomized studies by appropriate weighting [abstract]. DFG Research Unit 534, Final Symposium on statistical modeling and data analysis in clinical epidemiology. Freiburg, Germany, 25 June 2010 2010, 14. [Abstract book].
21. Schafer J.L., Kang J. Average causal effects from nonrandomized studies: a practical guide and simulated example. Psychol Methods 2008, 13:279-313.
22. Reeves B.C., Gaus W. Guidelines for reporting non-randomized studies. Forsch Komplementarmed Klass Naturheilkd 2004, 11(Suppl. 1):46-52.
23. Serafini G., Sconfienza L.M., Lacelli F., et al. Rotator cuff calcific tendonitis: short-term and 10-year outcomes after two-needle US-guided percutaneous treatment - nonrandomized controlled trial. Radiology 2009, 252:157-164.
24. Carlsson M., Arman M., Backman M., et al. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol 2004, 43:27-34. 10.1080/02841860310020339.
25. Silverman N.E., Nicklas B.J., Ryan A.S. Addition of aerobic exercise to a weight loss program increases BMD, with an associated reduction in inflammation in overweight postmenopausal women. Calcif Tissue Int 2009, 84:257-265. 10.1007/s00223-009-9232-z.
26. Gramenzi A., Andreone P., Fiorino S., et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001, 48:843-848.
27. Kelley J.M., Kaptchuk T.J. Group analysis versus individual response: the inferential limits of randomized controlled trials. Contemp Clin Trials 2010, 31:423-428.
28. Sackett D.L., Rosenberg W.M.C., Gray J.A.M., et al. Evidence based medicine: what it is and what it isn't. BMJ 1996, 312:71-72.
29. Silverman W.A. Patient preferences and randomized trials. Lancet 1994, 343:1586.
30. Schmoor C., Olschewski M., Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 1996, 15:263-271.